Status:
COMPLETED
Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
30-75 years
Phase:
PHASE1
Brief Summary
This trial is conducted in Europe. The aim of this trial is to examine the effect of NNC 90-1170 on the hypoglycaemic counterregulation in subjects with type 2 diabetes.
Eligibility Criteria
Inclusion
- age: minimum 30, maximum 75 years
Exclusion
Key Trial Info
Start Date :
April 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2001
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT01509742
Start Date
April 1 2001
End Date
November 1 2001
Last Update
February 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Bad Lauterberg im Harz, Germany, 37431